Complete FDA and NHTSA recall records dated in July 2025.
These records include useful source details for the selected month.
Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention sample testing at…
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Ford Motor Company (Ford) is recalling certain 2025 Lincoln Navigator, F-150, Expedition, Bronco, and Ranger vehicles. The Electronic Brake Booster (EBB) module may malfunction while…
Subpotent Drug: Assay below the approved specification
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25C, 60%RH).
Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.
Labeling: Incorrect or Missing Lot and/or Exp. Date: A printing issue resulted in incorrect lot numbers on the label.
Subpotent Drug: Assay below the approved specification
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Lack of Processing Controls; prescriptions were compounded in an ISO-5 area where it was identified that a daily cleaning step was not sufficiently documented.
Subpotent Drug: Assay below the approved specification
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet…
cGMP deviations
cGMP deviations
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Presence of Foreign Substance- Black hair strand found attached to a tablet in a sealed bottle.
cGMP deviations
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25C/60% RH) long-term.
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.
